Prognostic value of pretreatment serum fibrinogen in young patients with small cell lung cancer: A cross‐sectional study

Abstract

Abstract Objective To explored the prognostic value of pretreatment serum fibrinogen level in young patients with small cell lung cancer (SCLC). Methods The concentrations of serum fibrinogen of 183 young (<50 years old) SCLC patients were measured. The association of baseline serum fibrinogen level and clinical outcome was analyzed by survival analysis. Results Hyperfibrinogenemia was significantly associated with American Veterans Administration Lung Study Group stage and surgery treatment. The survival analysis indicated that patients with hypefibrinogenemia had worse outcome than patients with normal fibrinogen. Pretreatment serum fibrinogen level was identified as a worse independent survival predictor in young SCLC. The hazard ratio was 1.420 (95% confidence interval: 1.035−1.947). Conclusions Pretreatment serum fibrinogen is independent associated with overall survival in patients with young SCLC.

Keywords

• overall survival
• prognostic factor
• serum fibrinogen
• small cell lung cancer